East India Pharmaceutical Works Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 6.67 Cr
- Company Age 88 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 81.33 Cr
- Satisfied Charges ₹ 1.05 Cr
- Revenue Growth 8.92%
- Profit Growth 56.89%
- Ebitda 14.22%
- Net Worth 5.43%
- Total Assets 5.86%
About East India Pharmaceutical Works
East India Pharmaceutical Works Limited (EIPWL) was founded in India on 27 April 1936 and has a glorious history of 88 years and nine months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 6.67 Cr.
The company currently has active open charges totaling ₹81.33 Cr. The company has closed loans amounting to ₹1.05 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at East India Pharmaceutical Works Limited India are Somnath Ray as CFO and Jayeeta Sarkar as Company Secretary. Probir Roy, Dilip Samadar, Tapas Raychaudhury, and Nine other members serve as directors at the Company.
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24231WB1936PLC008598
- Company No.
008598
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 Apr 1936
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
What products or services does East India Pharmaceutical Works Limited offer?
East India Pharmaceutical Works Limited offers a wide range of products and services, including Common Disease Medicines, Psoriasis Ointment, Nutraceuticals & Dietary Supplements, Dietary Supplements, Cosmetics, Hair & Beauty Products, Body Care Products, Digestive System Drugs & Medicines, Digestive Drugs, Multivitamin Syrup & Drops, Antacid Drugs.
Who are the key members and board of directors at East India Pharmaceutical Works?
Executive Team (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Debarshi Duttagupta  | Managing Director | 30-Jun-2010 | Current |
| Satarupa Mukherjee | Managing Director | 07-May-2019 | Current |
| Somnath Ray | CFO | 16-Aug-2023 | Current |
| Jayeeta Sarkar | Company Secretary | 01-Nov-2019 | Current |
Board Members (10)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suman Mukerjee | Director | 04-Aug-2011 | Current |
| Probir Roy | Director | 25-Jul-2005 | Current |
| Dilip Samadar | Director | 22-Jul-2012 | Current |
| Tapas Raychaudhury | Director | 25-Mar-2015 | Current |
| Sukamal Basu | Director | 22-Jun-2010 | Current |
| Ajoy Chatterjee | Director | 20-Sep-2024 | Current |
Financial Performance of East India Pharmaceutical Works.
East India Pharmaceutical Works Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 8.92% increase. The company also saw a substantial improvement in profitability, with a 56.89% increase in profit. The company's net worth moved up by a moderate rise of 5.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of East India Pharmaceutical Works?
In 2021, East India Pharmaceutical Works had a promoter holding of 30.19% and a public holding of 69.80%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Patton International LtdProbir Roy is a mutual person
Jardine Henderson LimitedSuman Mukerjee is a mutual person
Industrial And Prudential Investment Company LimitedProbir Roy is a mutual person
Shalimar Wires Industries LimitedTrishna Guha is a mutual person
Century Plyboards (India) Ltd.Probir Roy is a mutual person
Bengal National Chamber Of Commerce & IndustryDebarshi Duttagupta is a mutual person
Charges (Loans)
₹81.33 Cr
₹1.05 Cr
Charges Breakdown by Lending Institutions
- Others : 64.34 Cr
- United Bank Of India : 16.99 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Nov 2024 | Others | ₹8.12 M | Open |
| 19 Sep 2024 | Others | ₹7.50 Cr | Open |
| 21 Jun 2024 | Others | ₹1.78 M | Open |
| 30 Apr 2024 | Others | ₹1.54 M | Open |
| 10 Oct 2023 | Others | ₹2.80 M | Open |
How Many Employees Work at East India Pharmaceutical Works?
East India Pharmaceutical Works has a workforce of 1560 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of East India Pharmaceutical Works, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped East India Pharmaceutical Works's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
